S. Collette

发表

Imaging biomarker roadmap for cancer studies

Stuart A. Taylor, Erich P Huang, J. Wason, 2016, Nature Reviews Clinical Oncology.

Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986.

R. Sylvester, J. Bellmunt, J. Lorent, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

EORTC Nomograms and Risk Groups for Predicting Recurrence, Progression, and Disease-specific and Overall Survival in Non-Muscle-invasive Stage Ta-T1 Urothelial Bladder Cancer Patients Treated with 1-3 Years of Maintenance Bacillus Calmette-Guérin.

L. Collette, T. D. de Reijke, R. Sylvester, 2016, European urology.

Internal Mammary and Medial Supraclavicular Irradiation in Breast Cancer.

Laurence Collette, Rodrigo Arriagada, Erik Van Limbergen, 2015, The New England journal of medicine.

Normal tissue complication probability (NTCP) parameters for breast fibrosis: pooled results from two randomised trials.

H. Bartelink, P. Evans, J. Yarnold, 2013, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

6LBA The benefit of regional irradiation in stage I–III breast cancer: 10 years results of the EORTC ROG and BCG phase III trial 22922/10925

H. Bartelink, V. Budach, P. Maingon, 2014 .

Adjuvant postoperative high-dose radiotherapy for atypical and malignant meningioma: A phase-II parallel non-randomized and observation study (EORTC 22042-26042).

L. Collette, Yan Liu, A. Pica, 2018, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Prognostic Factors for Local Control in Breast Cancer After Long-term Follow-up in the EORTC Boost vs No Boost Trial: A Randomized Clinical Trial

E. van Limbergen, H. Bartelink, J. Horiot, 2017, JAMA oncology.

OC-0523: Lymph node RT improves survival in breast cancer: 10 years results of the EORTC ROG and BCG phase III trial 22922/10925.

H. Bartelink, V. Budach, P. Maingon, 2014 .

Crizotinib achieves long-lasting disease control in advanced papillary renal-cell carcinoma type 1 patients with MET mutations or amplification. EORTC 90101 CREATE trial.

J. Šufliarský, P. Rutkowski, M. Debiec‐Rychter, 2017, European journal of cancer.

The tyrosine kinase inhibitor crizotinib does not have clinically meaningful activity in heavily pre-treated patients with advanced alveolar rhabdomyosarcoma with FOXO rearrangement: European Organisation for Research and Treatment of Cancer phase 2 trial 90101 'CREATE'.

S. Aamdal, R. Sciot, B. Geoerger, 2018, European journal of cancer.

Comparison of Local Control of Brain Metastases With Stereotactic Radiosurgery vs Surgical Resection: A Secondary Analysis of a Randomized Clinical Trial

L. Collette, R. Soffietti, B. Alexander, 2019, JAMA oncology.

Phase 3 trials of stereotactic radiosurgery with or without whole-brain radiation therapy for 1 to 4 brain metastases: individual patient data meta-analysis.

J. Beyene, A. Sahgal, S. Collette, 2015, International journal of radiation oncology, biology, physics.

A risk management approach for imaging biomarker-driven clinical trials in oncology.

H. Kauczor, L. Shankar, Yan Liu, 2015, The Lancet. Oncology.

RandomizedPhaseIIIStudyComparingPaclitaxel/Cisplatin/ GemcitabineandGemcitabine/CisplatininPatientsWithLocally AdvancedorMetastaticUrothelialCancerWithoutPriorSystemic Therapy:EORTCIntergroupStudy30987

R. Sylvester, M. Santis, L. Paz-Ares, 2012 .

Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC Intergroup Study 30987.

R. Sylvester, L. Paz-Ares, J. Bellmunt, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Superior outcome of women with stage I/II cutaneous melanoma: pooled analysis of four European Organisation for Research and Treatment of Cancer phase III trials.

J. Coebergh, A. Eggermont, T. Nijsten, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Sex is an independent prognostic indicator for survival and relapse/progression-free survival in metastasized stage III to IV melanoma: a pooled analysis of five European organisation for research and treatment of cancer randomized controlled trials.

J. Coebergh, A. Eggermont, T. Nijsten, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A prospective, randomised EORTC intergroup phase 3 study comparing the oncologic outcome of elective nephron-sparing surgery and radical nephrectomy for low-stage renal cell carcinoma.

R. Sylvester, L. D. Pozzo, M. Colombel, 2011, European urology.

Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma.

J. Witjes, M. Galsky, M. Milowsky, 2021, The New England journal of medicine.

Immediate versus deferred cytoreductive nephrectomy (CN) in patients with synchronous metastatic renal cell carcinoma (mRCC) receiving sunitinib (EORTC 30073 SURTIME)

L. Collette, B. Tombal, R. Velthoven, 2017 .

Whole brain radiotherapy after stereotactic radiosurgery or surgical resection among patients with one to three brain metastases and favorable prognoses: a secondary analysis of EORTC 22952-26001

L. Collette, R. Soffietti, B. Alexander, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Changes of ferritin and CRP levels in melanoma patients treated with adjuvant interferon-&agr; (EORTC 18 952) and prognostic value on treatment outcome

A. Eggermont, S. Collette, L. Aarden, 2011, Melanoma research.

Whole-breast irradiation with or without a boost for patients treated with breast-conserving surgery for early breast cancer: 20-year follow-up of a randomised phase 3 trial.

E. van Limbergen, H. Bartelink, J. Horiot, 2015, The Lancet. Oncology.

Wilms tumor 1 (WT1) gene mutations in pediatric T-cell malignancies

E. Clappier, H. Cavé, C. Preudhomme, 2009, Leukemia.

Prognosis of hepatocellular carcinoma (HCC): Comparison of four staging systems in two French clinical trials

X. Paoletti, P. Rougier, O. Bouché, 2007 .

Autoimmune antibodies and recurrence-free interval in melanoma patients treated with adjuvant interferon.

S. Aamdal, A. Eggermont, C. Punt, 2009, Journal of the National Cancer Institute.

A multicentre observational study evaluating image-guided radiotherapy for more accurate partial-breast intensity-modulated radiotherapy: comparison with standard imaging technique

H. Bartelink, P. Evans, J. Yarnold, 2014 .

Final results of an EORTC-GU cancers group randomized study of maintenance bacillus Calmette-Guérin in intermediate- and high-risk Ta, T1 papillary carcinoma of the urinary bladder: one-third dose versus full dose and 1 year versus 3 years of maintenance.

R. Sylvester, G. van Andel, S. Collette, 2013, European urology.

Activity and safety of crizotinib in patients with alveolar soft part sarcoma with rearrangement of TFE3: European Organization for Research and Treatment of Cancer (EORTC) phase II trial 90101 ‘CREATE’

J. Blay, S. Aamdal, R. Sciot, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

NOTCH1 and FBXW7 mutations have a favorable impact on early response to treatment, but not on outcome, in children with T-cell acute lymphoblastic leukemia (T-ALL) treated on EORTC trials 58881 and 58951

F. Speleman, E. Clappier, H. Cavé, 2010, Leukemia.

Nivolumab in Patients with Advanced Platinum-resistant Urothelial Carcinoma: Efficacy, Safety, and Biomarker Analyses with Extended Follow-up from CheckMate 275

M. Galsky, P. Sharma, P. Szabo, 2020, Clinical Cancer Research.

Predictors of the risk of fibrosis at 10 years after breast conserving therapy for early breast cancer: a study based on the EORTC Trial 22881-10882 'boost versus no boost'.

Michel Bolla, Laurence Collette, John Kurtz, 2008, European journal of cancer.

Prognosis of advanced hepatocellular carcinoma: comparison of three staging systems in two French clinical trials.

X. Paoletti, P. Rougier, O. Bouché, 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: results of the EORTC 22952-26001 study.

L. Collette, R. Soffietti, F. Fauchon, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Nivolumab in patients with unresectable locally advanced or metastatic urothelial carcinoma: CheckMate 275 2-year global and Japanese patient population analyses

M. Galsky, P. Sharma, E. Kikuchi, 2019, International Journal of Clinical Oncology.

Comparison of Immediate vs Deferred Cytoreductive Nephrectomy in Patients With Synchronous Metastatic Renal Cell Carcinoma Receiving Sunitinib: The SURTIME Randomized Clinical Trial

R.C.E. van Velthoven, L. Collette, B. Tombal, 2019, JAMA oncology.

PD10-01 DISEASE-FREE SURVIVAL WITH LONGER FOLLOW-UP FROM THE CHECKMATE 274 TRIAL OF ADJUVANT NIVOLUMAB IN PATIENTS AFTER SURGERY FOR HIGH-RISK MUSCLE-INVASIVE UROTHELIAL CARCINOMA

J. Witjes, M. Galsky, D. Bajorin, 2022, Journal of Urology.

Crizotinib in patients with advanced, inoperable inflammatory myofibroblastic tumours with and without anaplastic lymphoma kinase gene alterations (European Organisation for Research and Treatment of Cancer 90101 CREATE): a multicentre, single-drug, prospective, non-randomised phase 2 trial.

J. Blay, R. Sciot, A. Italiano, 2018, The Lancet. Respiratory medicine.

European Organization for Research and Treatment of Cancer phase 2 trial 90101 " CREATE "

Birgit, R. Sciot, P. Rutkowski, 2017 .

Circulating melanoma cells and distant metastasis-free survival in stage III melanoma patients with or without adjuvant interferon treatment (EORTC 18991 side study).

A. Eggermont, A. Testori, C. Punt, 2009, European journal of cancer.

Quality of life as a prognostic factor of overall survival in patients with advanced hepatocellular carcinoma: results from two French clinical trials

X. Paoletti, P. Rougier, S. Collette, 2008, Quality of Life Research.

Sequential intravesical chemoimmunotherapy with mitomycin C and bacillus Calmette-Guérin and with bacillus Calmette-Guérin alone in patients with carcinoma in situ of the urinary bladder: results of an EORTC genito-urinary group randomized phase 2 trial (30993).

C. Busch, R. Sylvester, F. Algaba, 2011, European urology.

Radiotherapy quality assurance for the RTOG 0834/EORTC 26053-22054/NCIC CTG CEC.1/CATNON intergroup trial "concurrent and adjuvant temozolomide chemotherapy in newly diagnosed non-1p/19q deleted anaplastic glioma": Individual case review analysis.

Yan Liu, Damien C Weber, Enrico Clementel, 2018, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Statistical methodology for personalized medicine: New developments at EORTC Headquarters since the turn of the 21st Century

L. Collette, T. Gorlia, S. Litière, 2012 .

Quality assurance of radiotherapy in the ongoing EORTC 1219-DAHANCA-29 trial for HPV/p16 negative squamous cell carcinoma of the head and neck: Results of the benchmark case procedure.

J. Kazmierska, V. Grégoire, M. Tomsej, 2017, Radiotherapy and Oncology.

LungTech, an EORTC Phase II trial of stereotactic body radiotherapy for centrally located lung tumours: a clinical perspective.

U Nestle, D De Ruysscher, D. de Ruysscher, 2015, The British journal of radiology.

Functional and molecular imaging in cancer drug development

Yan Liu, S. Collette, V. Bollineni, 2014 .

Adjuvant nivolumab versus placebo following radical surgery for high-risk muscle-invasive urothelial carcinoma: a subgroup analysis of Japanese patients enrolled in the phase 3 CheckMate 274 trial

M. Galsky, D. Bajorin, M. Oya, 2022, Japanese journal of clinical oncology.

Disease-free Survival Analysis for Patients with High-risk Muscle-invasive Urothelial Carcinoma from the Randomized CheckMate 274 Trial by PD-L1 Combined Positive Score and Tumor Cell Score.

Jun Yu Li, J. Witjes, M. Galsky, 2023, European urology.

First results from the phase 3 CheckMate 274 trial of adjuvant nivolumab vs placebo in patients who underwent radical surgery for high-risk muscle-invasive urothelial carcinoma (MIUC).

J. Witjes, M. Galsky, D. Bajorin, 2021 .

RECIST — learning from the past to build the future

Lesley Seymour, Saskia Litière, Elisabeth G. E. de Vries, 2017, Nature Reviews Clinical Oncology.

Concordance measures in shared frailty models: application to clustered data in cancer prognosis

Virginie Rondeau, Audrey Mauguen, J. Pignon, 2013, Statistics in medicine.

Quality assurance of radiotherapy in the ongoing EORTC 22042–26042 trial for atypical and malignant meningioma: results from the dummy runs and prospective individual case Reviews

W. Straube, C. Hurkmans, S. Collette, 2013, Radiation Oncology.

Abstract CT006: Crizotinib achieves objective responses and long-lasting disease control in patients (pts) with metastatic papillary renal cell carcinoma type 1 (PRCC1) with somaticMETmutations. EORTC phase II trial 90101 “CREATE”

J. Šufliarský, P. Rutkowski, E. Lerut, 2016 .

Analysis of disease-free survival in CheckMate 274 by PD-L1 combined positive score and tumor proportion score.

J. Witjes, M. Galsky, D. Bajorin, 2022, Journal of Clinical Oncology.

Fifteen-year results of the randomised EORTC trial 22922/10925 investigating internal mammary and medial supraclavicular (IM-MS) lymph node irradiation in stage I-III breast cancer.

H. Bartelink, V. Budach, R. Abdah-bortnyak, 2018 .

Retrospective quality control review of FDG scans in the imaging sub-study of PALETTE EORTC 62072/VEG110727: a randomized, double-blind, placebo-controlled phase III trial

W. Oyen, R. Boellaard, F. Mottaghy, 2015, European Journal of Nuclear Medicine and Molecular Imaging.

Results from a Phase I Study of Lapatinib with Gemcitabine and Cisplatin in Advanced or Metastatic Bladder Cancer: EORTC Trial 30061

C. Sternberg, L. Cerbone, C. V. van Herpen, 2015, Oncology.

Prognostic Significance of NOTCH1 and FBXW7 Mutations in Childhood T-Cell Acute Lymphoblastic Leukemia (T-ALL): Results From the EORTC Children Leukemia Group.

F. Speleman, E. Clappier, H. Cavé, 2009 .

Surgical Safety of Cytoreductive Nephrectomy Following Sunitinib: Results from the Multicentre, Randomised Controlled Trial of Immediate Versus Deferred Nephrectomy (SURTIME).

L. Collette, C. Blank, J. Haanen, 2019, European urology.

Individual Patient Data (IPD) Meta-Analysis of Randomized Controlled Trials (RCT) Comparing Stereotactic Radiosurgery Alone to SRS Plus Whole Brain Radiation Therapy in Patients With Brain Metastasis

J. Beyene, A. Sahgal, S. Collette, 2013 .

Repeatability and reproducibility of relative cerebral blood volume measurement of recurrent glioma in a multicentre trial setting.

S. Heiland, M. J. van den Bent, Yan Liu, 2019, European journal of cancer.

Stereotactic body radiotherapy for central lung tumours: Author reply.

D. de Ruysscher, R. Dziadziuszko, C. Faivre-Finn, 2015, The British journal of radiology.

Internal Mammary and Medial Supraclavicular Irradiation in Breast Cancer.

E. van Limbergen, I. Barillot, S. Marnitz, 2015, The New England journal of medicine.

Reply to ‘Interpretation of concordance measures for clustered data’

J. Pignon, V. Rondeau, S. Collette, 2014, Statistics in medicine.

R. Sylvester, G. van Andel, S. Collette, 2013, European urology.